Business Summary
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company headquartered in Cambridge, MA, focused on developing oral small molecule therapies for genetically defined rare diseases. Its lead asset, pociredir, is an EED inhibitor designed to induce fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD), with Phase 1b data showing clinically meaningful HbF induction and hemolysis improvements. The company has no approved products and is pre-revenue, with a $594.3 million accumulated deficit as of December 31, 2025.
Products & Services
- Pociredir (lead asset): Oral small molecule EED inhibitor for SCD; completed dosing in Phase 1b PIONEER trial at 20mg dose
- 20mg cohort: Mean HbF increased from 7.1% to 19.3% at week 12; 58% achieved HbF >= 20%
- Mean hemoglobin increased by 1.1 g/dL; hemolysis markers improved (40% decrease in indirect bilirubin, 34% drop in LDH)
- 6 VOCs reported vs. 16 expected; 58%...
AI-generated summary of Item 1 (Business) from the 10-K filed Feb 24, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Institutional holders · 13F
Q2 2026| Largest holders | Reported value |
|---|---|
| BlackRock Inc | $32.3M |
| EcoR1 Capital LLC | $24.0M |
| TANG CAPITAL MANAGEMENT LLC | $23.9M |
| Nantahala Capital Management LLC | $20.0M |
| SUVRETTA CAPITAL MANAGEMENT LLC | $13.5M |
5%+ holders · 13D/G
6 filers| Filer | % of class | Filed |
|---|---|---|
| BlackRock Portfolio Management LLC 13G | 8.1% | 2026-10-27 |
| Nantahala Capital Management LLC 13G | 8.2% | 2026-08-14 |
| SUVRETTA CAPITAL MANAGEMENT LLC 13G | 5.5% | 2026-08-14 |
| BlackRock Inc 13G | 7.2% | 2026-07-28 |
| TANG CAPITAL MANAGEMENT LLC 13G | 10.4% | 2026-07-15 |
| EcoR1 Capital LLC 13G | 9.0% | 2026-06-25 |
Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.
Federal lobbying · LD-2
Securities
| CUSIP | Security | Type |
|---|---|---|
| 359616109 | FULC FULCRUM THERAPEUTICS INC | Common stock |
Insider trades · Form 4
Annual results · 10-K
Fiscal 2025- Revenue
- $0
- Net loss
- -$74.9M
As reported in the fiscal 2025 annual report.
Funds & ETFs · N-PORT
160 funds| Fund | Value | % of fund |
|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI | $7.6M | < 0.01% |
| BlackRock Advantage Small Cap Core Fund | $5.8M | 0.1% |
| iShares Russell 2000 ETF IWM | $5.7M | < 0.01% |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF XPH | $3.0M | 0.69% |
| Fidelity Small Cap Index Fund | $2.3M | < 0.01% |
| iShares Russell 2000 Value ETF IWN | $2.1M | 0.01% |
| VANGUARD EXTENDED MARKET INDEX FUND | $2.0M | < 0.01% |
| iShares Biotechnology ETF IBB | $1.5M | 0.02% |
| VANGUARD RUSSELL 2000 INDEX FUND VTWO | $1.3M | < 0.01% |
| Strategic Advisers U.S. Total Stock Fund | $1.1M | < 0.01% |
160 funds reported holding $50.8M in total on their latest public Form N-PORT reports, the most recent dated August 2026. Security record